Please login to the form below

Not currently logged in
Email:
Password:

Atopic dermatitis

This page shows the latest Atopic dermatitis news and features for those working in and with pharma, biotech and healthcare.

NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis

NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis

LEO Pharma has announced that its biologic treatment for moderate-to-severe atopic dermatitis, Adtralza (tralokinumab), has been issued a final appraisal document for recommendation by the National Institute for Health ... The four studies showed that

Latest news

More from news
Approximately 16 fully matching, plus 86 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    pneumococcal vaccine due to be filed next year that would extend its $3.4bn Prevnar franchise, a Clostridium difficile vaccine in phase 3 and JAK inhibitors for atopic dermatitis and alopecia.

  • Case study: See Below Case study: See Below

    We needed to pique delegates’ interest and show them a new approach to treating atopic dermatitis. ... But, how? Before diving head-first into the idea, we enlisted the help of key stakeholders within atopic dermatitis.

  • Innovation and digital health comms recognised at Communiqué Awards Innovation and digital health comms recognised at Communiqué Awards

    The video played while the lift whisked its passengers into the congress, creating a six-minute video ‘experience’ which challenged dermatologists to change the way they treated atopic dermatitis. ... In order to target their message, the creative

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... Likewise, upadacitinib will face competition in both RA and atopic dermatitis,

  • Leo has its eyes on the prize Leo has its eyes on the prize

    Innovation investment. Leo has the big beasts of psoriasis and atopic dermatitis firmly in its sights and is forging ahead on the quest to tackle unmet needs in dermatology. ... Bridging the gap. Leo is tracking increases in atopic dermatitis across

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....